Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Show more

170 Harbor Way, South San Francisco, CA, 94080, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

153.6M

52 Wk Range

$0.26 - $0.84

Previous Close

$0.59

Open

$0.58

Volume

212,247

Day Range

$0.57 - $0.64

Enterprise Value

74.52M

Cash

28.79M

Avg Qtr Burn

N/A

Insider Ownership

0.93%

Institutional Own.

0.05%

Qtr Updated

09/30/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2b

Data readout

Phase 2b

Update

Phase 2

Update

Phase 2

Update

Phase 1

Data readout

Phase 1

Update